Leadership in Dialysis Services and Products Drives FMS Stock
- Fresenius Medical Care leads global dialysis services, driving growth through innovation, restructuring and a strong global footprint in 120+ countries.
- 12/17/2024
|
Are Investors Undervaluing Fresenius Medical Care AG & Co. (FMS) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 12/05/2024
|
Here's Why Fresenius (FMS) is a Strong Value Stock
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 12/03/2024
|
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 11/14/2024
|
Is Fresenius Medical Care AG & Co. (FMS) Stock Undervalued Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 11/11/2024
|
Fresenius Medical Q3 Earnings Beat Estimates, Operating Margin Rises
- FMS' third-quarter results showcase a strong segmental performance. The company raises its full-year 2024 outlook for operating income.
- 11/06/2024
|
Fresenius (FMS) is a Top-Ranked Momentum Stock: Should You Buy?
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 11/06/2024
|
Hard work paying off despite challenges from U.S. weather-related events: Fresenius Medical Care CEO
- Helen Giza, the CEO of Fresenius Medical Care, discusses the German healthcare firm's third-quarter earnings.
- 11/05/2024
|
Fresenius Medical Care AG (FMS) Q3 2024 Earnings Call Transcript
- Fresenius Medical Care AG (NYSE:FMS ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chief Executive Officer and Chair Martin Fischer - Chief Financial Officer Conference Call Participants Richard Felton - Goldman Sachs Victoria Lambert - Berenberg Robert Davies - Morgan Stanley Hugo Solvet - BNP Paribas Oliver Metzger - ODDO BHF Bank Sezgi Oezener - HSBC Giang Nguyen - Citigroup David Adlington - JPMorgan Marianne Bulot - Bank of America Falko Friedrichs - Deutsche Bank Christian Ehmann - Warburg Research Operator Ladies and gentlemen, welcome to the report of the Third Quarter 2024 of Fresenius Medical Care Conference Call. I'm Sandra, the Chorus Call operator.
- 11/05/2024
|
Fresenius Medical Care reports strong operating income margin growth in the third quarter of 2024
- Organic revenue growth of +2% supported by Care Enablement and Care Delivery Underlying U.S. dialysis treatment volume growth turns positive Exceeding full year FME25 savings target, with additional EUR 64 million contribution in Q3 Both segments further increased operating income1 and operating income margin1 Net financial leverage ratio further improved to 2.8x FY 2024 operating income1 growth outlook with 16-18% tightened toward the upper end of the previous range BAD HOMBURG, Germany , Nov. 5, 2024 /PRNewswire/ -- "In the third quarter, we continued the improvement of our financial performance, recording a meaningful progress in the operating income margin towards our 2025 margin targets. The Care Delivery margin extended well into the 2025 margin target band while Care Enablement maintained the significant margin progress realized in the first half year.
- 11/05/2024
|
Should Value Investors Buy Fresenius Medical Care AG & Co. (FMS) Stock?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 10/22/2024
|
Fresenius Medical Care Showcases Research and Innovations in Kidney Care at American Society of Nephrology (ASN) Kidney Week 2024
- A dedicated session will highlight new advancements in hemodiafiltration therapy showcasing its potential to improve patient outcomes through enhanced toxin removal in dialysis treatments. Company-wide researchers and clinical experts share insights from large global databases, revealing crucial trends in kidney failure etiology, cardiovascular risks, and treatment modalities across different regions.
- 10/21/2024
|
Here's Why Fresenius (FMS) is a Strong Value Stock
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 10/08/2024
|
Fresenius Medical Care: Let's Look At The Upside
- Fresenius Medical Care is a BBB-rated leader in kidney care with a 3.1% yield, undervalued at 14x P/E, and poised for growth by 2025-2026E. Despite recent earnings declines, the company expects growth in 2024, driven by global ESRD demand, at-home treatments, and strategic divestments. Political risks exist, but Fresenius' market-leading position, leverage improvements, and 35% market share in equipment support a "Buy" rating with a $34/share PT.
- 10/04/2024
|
Here's Why Fresenius (FMS) is a Strong Momentum Stock
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 10/04/2024
|
FMS Stock Rides on Diversified Portfolio and Restructuring Initiatives
- Fresenius Medical Care's diversified portfolio helps to fight competition and maintain market leadership.
- 10/03/2024
|
Reasons to Retain Fresenius Medical Stock in Your Portfolio Now
- FMS continues to gain traction on the back of its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.
- 09/27/2024
|
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 09/20/2024
|
Why Fresenius (FMS) is a Top Momentum Stock for the Long-Term
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 09/18/2024
|
Fresenius Medical Care Stock Rises on NxStage VersiHD Launch
- FMS introduces NxStage VersiHD with GuideMe Software to simplify home dialysis and grow its patient base in the United States.
- 09/09/2024
|
Fresenius Medical Care Grows Number of U.S. Patients Using Company's Home Hemodialysis Machines, Launches NxStage® Versi®HD with GuideMe Software
- Fresenius Medical Care achieves growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage systems to perform Home Hemodialysis therapy This growth has generated greater adoption from a range of dialysis providers and delivers on the company's commitment to grow access to and use of home dialysis therapy The newest NxStage® Versi®HD with GuideMe Software home dialysis machine is designed to simplify treatment, increase ease of learning, and improve user experience WALTHAM, Mass. , Sept. 4, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), a global leader in kidney care, has achieved a growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage systems to perform Home Hemodialysis (HHD) therapy through both Fresenius Kidney Care clinics and other providers.
- 09/04/2024
|
Reasons to Retain Fresenius Medical Stock in Your Portfolio Now
- FMS continues to gain traction through its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.
- 08/27/2024
|
Marvell to Showcase Latest Cloud Storage and CXL Memory Technologies at FMS 2024
- Awarded Most Innovative Sustainability Technology for Marvell® Structera™ X CXL Memory-Expansion Controller SANTA CLARA, Calif. , Aug. 7, 2024 /PRNewswire/ -- Marvell Technology, Inc. (NASDAQ: MRVL), a leader in data infrastructure semiconductor solutions, today announced it will showcase its industry-leading cloud storage and CXL memory technologies for AI, ML and other data-intensive workloads at the Flash Memory Summit, taking place August 6–8, 2024 at the Santa Clara Convention Center.
- 08/07/2024
|
Fresenius Medical Care CEO says strategy is working as company delivers on transformation efforts
- Fresenius Medical Care CEO Helen Giza comments on the firm's second-quarter earning results.
- 07/30/2024
|
Fresenius Medical (FMS) Q2 Earnings In Line, Operating Margin Up
- Fresenius Medical's (FMS) second-quarter revenues suffer due to divestures. However, the company?
- 07/30/2024
|
Fresenius Medical Care AG (FMS) Q2 2024 Earnings Call Transcript
- Fresenius Medical Care AG (NYSE:FMS ) Q2 2024 Earnings Call July 30, 2024 8:00 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chief Executive Officer and Chair Martin Fischer - Chief Financial Officer Conference Call Participants Veronika Dubajova - Citi Richard Felton - Goldman Sachs Graham Doyle - UBS Hassan Al-Wakeel - Barclays Victoria Lambert - Berenberg Hugo Solvet - BNP Paribas James Vane-Tempest - Jefferies David Adlington - JPMorgan Falko Friedrichs - Deutsche Bank Robert Davies - Morgan Stanley Marianne Bulot - Bank of America Dominik Heger Thank you, Alice. Good morning, good afternoon or good evening, depending on where you are.
- 07/30/2024
|
Fresenius Medical Care delivers continued operating income improvements in the second quarter of 2024
- Organic revenue growth of +2.3% supported by both segments Care Delivery and Care Enablement Operating income1 and operating income margin1 increase driven by Care Enablement Additional FME25 savings of EUR 57 million achieved and on track to reach the upper end of the full year savings target range Further divestitures closed as execution of portfolio optimization program continues Net financial debt and net leverage ratio further improved FY 2024 outlook confirmed BAD HOMBURG, Germany , July 30, 2024 /PRNewswire/ -- "In the second quarter, we further improved our financial performance while executing against our strategic plan and the company transformation. This quarter is another important proof point for the operational turnaround as we remain focused to deliver on our targets", said Helen Giza, Chief Executive Officer of Fresenius Medical Care AG.
- 07/30/2024
|
Here's Why Fresenius (FMS) is a Strong Value Stock
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 07/23/2024
|
US FTC probing DaVita, Fresenius Medical, Politico reports
- The U.S. Federal Trade Commission (FTC) is investigating healthcare providers DaVita and Fresenius Medical Care over allegations that the companies have been illegally thwarting smaller competitors, Politico reported on Saturday, citing three people familiar with the matter.
- 07/13/2024
|
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
- Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
- 07/08/2024
|
Bridger Aerospace Acquires FMS Aerospace, Boosting In-House Engineering Capabilities and Diversifying its Customer Base and Seasonality
- BELGRADE, Mont., July 01, 2024 (GLOBE NEWSWIRE) -- Bridger Aerospace Group Holdings, Inc. (“Bridger”, “the Company” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation's largest aerial firefighting companies, today announced that it has acquired FMS Aerospace (“FMS”). FMS, based in Huntsville, Alabama, is a turn-key provider of airframe modification and integration solutions for government and commercial customers including instrumentation, flight testing and airworthiness certification. The consideration for the transaction was $17.51 million in equity, with an additional contingent equity earn-out consideration of up to $3.09 million.
- 07/01/2024
|
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 06/19/2024
|
Fresenius Medical Care takes next important step towards goal to reduce CO2 emissions in its operations
- Fresenius Medical Care enters virtual power purchase agreements for renewable energy to clearly step forward in reducing CO2 emissions footprint Company enacts five virtual power purchase agreements for around 580 gigawatt hours per year with wind and solar farms in Germany and the U.S. Energy farms scheduled to go into operation in 2024 and 2025 Important milestone for strategic sustainability goal to achieve climate-neutrality by 2040 BAD HOMBURG, Germany , June 12, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, has signed five virtual power purchase agreements (vPPAs) with wind and solar energy project developers in Germany and the U.S. The projects are expected to feed around 580 gigawatt hours of renewable energy into the grid, which equals up to 46 percent of FME's most recently reported global consumption. The company is thus taking an important step towards its goal of reducing emissions in its own operations (Scope 1 and 2) by 50 percent by 2030.
- 06/12/2024
|
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
- Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
- 06/07/2024
|
Ozempic cuts kidney-disease risks, research finds
- Novo Nordisk's diabetes drug Ozempic reduces the risk of kidney failure and death in patients who have both Type 2 diabetes and chronic kidney disease, according to new research published Friday in the New England Journal of Medicine.
- 05/24/2024
|
Moody's and S&P change Fresenius Medical Care's rating outlook to stable
- The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating FME is expected to maintain its good growth momentum, while continuing to improve operational performance on the back of its strong transformation progress Solid deleveraging prospects BAD HOMBURG, Germany , May 23, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today received from S&P Global, a leading rating agency, the change of its rating outlook to stable from negative (bbb-, stable outlook). Moody's changed the credit rating outlook from negative to stable on May 17 (baa3, stable outlook).
- 05/23/2024
|
Fresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European Renal Association (ERA) Congress 2024
- Enhancing kidney care through innovative approaches by data-driven insights and real-world evidence Company-wide experts highlight robust anonymized dialysis database CONVINCE study and the remarkable decrease of 23% in mortality rates for patients treated with high-volume hemodiafiltration will be presented BAD HOMBURG, Germany , May 21, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the presentation of nearly 40 company-affiliated research abstracts at the 61st European Renal Association (ERA) Congress, taking place May 23-26, 2024, in Stockholm, Sweden and virtually. "Our mission to improve the lives of people living with kidney disease requires working continually to enhance the standard of kidney disease care, and research plays an important role in that advancement," said Dr. Frank Maddux, Global Chief Medical Officer and Member of the Management Board for Fresenius Medical Care.
- 05/21/2024
|
Analyzing Ryder System (NYSE:R) and Zoomcar (NASDAQ:ZCAR)
- Ryder System (NYSE:R – Get Free Report) and Zoomcar (NASDAQ:ZCAR – Get Free Report) are both transportation companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings. Profitability This table compares Ryder System and Zoomcar’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Ryder System 2.95% 18.38% 3.62% Zoomcar N/A -13.53% 48.39% Analyst Recommendations This is a breakdown of current ratings and recommmendations for Ryder System and Zoomcar, as reported by MarketBeat. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ryder System 0 5 2 0 2.29 Zoomcar 0 0 0 0 N/A Ryder System presently has a consensus target price of $126.83, indicating a potential upside of 0.88%. Given Ryder System’s higher possible upside, analysts plainly believe Ryder System is more favorable than Zoomcar. Institutional & Insider Ownership 87.5% of Ryder System shares are owned by institutional investors. Comparatively, 3.7% of Zoomcar shares are owned by institutional investors. 5.1% of Ryder System shares are owned by insiders. Comparatively, 2.2% of Zoomcar shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Risk and Volatility Ryder System has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Zoomcar has a beta of -0.31, suggesting that its share price is 131% less volatile than the S&P 500. Earnings & Valuation This table compares Ryder System and Zoomcar’s revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ryder System $12.07 billion 0.46 $406.00 million $7.68 16.37 Zoomcar $9.87 million 1.56 -$4.63 million N/A N/A Ryder System has higher revenue and earnings than Zoomcar. Summary Ryder System beats Zoomcar on 9 of the 11 factors compared between the two stocks. About Ryder System (Get Free Report) Ryder System, Inc. operates as a logistics and transportation company worldwide. It operates through three segments: Fleet Management Solutions (FMS), Supply Chain Solutions (SCS), and Dedicated Transportation Solutions (DTS). The FMS segment offers full-service leasing and leasing with flexible maintenance options; commercial vehicle rental services; and contract or transactional maintenance services of trucks, tractors, and trailers; access to diesel fuel; and fuel planning and tax reporting, cards, and monitoring services, and centralized billing, as well as sells used vehicles through its retail sales centers and www.ryder.com/used-trucks website, as well as digital and technology support services. The DTS segment offers equipment, maintenance, drivers, administrative, and additional services, as well as routing and scheduling, fleet sizing, safety, regulatory compliance, risk management, and technology and communication systems support services. The SCS segment comprises distribution management services, such as designing and managing customer's distribution network and facilities; coordinating warehousing and transportation for inbound and outbound material flows; handling import and export for international shipments; coordinating just-in-time replenishment of component parts to manufacturing and final assembly; and offering shipments to customer distribution centers or end customer delivery points, as well as other value added services, such as light assembly of components. This segment also offers transportation management and brokerage services, such as shipment optimization, load scheduling, and delivery confirmation services; knowledge-based professional services; and e-commerce and last mile services. The company was founded in 1933 and is headquartered in Coral Gables, Florida. About Zoomcar (Get Free Report) Zoomcar Holdings, Inc. operates a marketplace for car sharing in India, Indonesia, and Egypt. It connects hosts with guests, who choose from a selection of cars for use at affordable prices, promoting smart transportation solutions. The company was founded in 2013 and is based in Bronxville, New York.
- 05/20/2024
|
Fresenius Medical Care Annual General Meeting: Company makes significant progress in its Transformation Efforts and confirms its ambitious 2024 Growth Targets
- Today's Annual General Meeting was the first one following the change in legal form completed in November 2023 Shareholders voted in favor of the proposed dividend of 1.19 euros, representing an increase of around 6 percent compared to the previous year New compensation system for Management Board approved Ambitious growth targets for 2024 confirmed BAD HOMBURG, Germany , May 16, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the global leader in providing products and services for people with kidney diseases, is executing its strategic turnaround plan and is well on track to achieve its goals for 2024. At today's Annual General Meeting, Michael Sen , Chairman of the Supervisory Board of Fresenius Medical Care AG, said: "Fresenius Medical Care has made significant progress in 2023.
- 05/16/2024
|
Fresenius Medical sees up to 2% US dialysis growth by year-end
- The number of kidney dialysis sessions provided by Fresenius Medical Care in its top market, the United States, could rise by as much as 2% by the end of the year, its CEO said, as the impact of the pandemic on patients fades.
- 05/11/2024
|
Fresenius Medical (FMS) Q1 Earnings Beat, Operating Margin Up
- Fresenius Medical's (FMS) first-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.
- 05/08/2024
|
Fresenius Medical Care AG (FMS) Q1 2024 Earnings Call Transcript
- Fresenius Medical Care AG (NYSE:FMS ) Q1 2024 Earnings Conference Call May 7, 2024 8:00 AM ET Company Participants Dominik Heger - Head, IR Helen Giza - CEO and Chair Martin Fischer - CFO Conference Call Participants Richard Felton - Goldman Sachs Victoria Lambert - Berenberg James Vane-Tempest - Jefferies Veronika Dubajova - Citi Graham Doyle - UBS Lisa Clive - Bernstein Robert Davies - Morgan Stanley Hugo Solvet - Exane BNP Paribas Oliver Metzger - ODDO BHF Falko Friedrichs - Deutsche Bank Dominik Heger Thank you, Alice. Good afternoon or good morning, depending on where you are.
- 05/07/2024
|
We have positive momentum in operating performance: Fresenius Medical Care CEO
- Helen Giza, CEO of Fresenius Medical Care, joins CNBC's Annette Weisbach to discuss the company's 2024 first-quarter earnings results.
- 05/07/2024
|
Fresenius Medical Care starts the year with strong earnings growth
- Solid revenue1 growth of 4% driven by both segments Care Delivery and Care Enablement Operating income1 margin improved in both segments Care Enablement delivered strong sequential margin improvement with significant progress towards the 2025 target margin band Execution of transformation continues at pace, contributing additional FME25 savings of EUR 52 million Portfolio optimization program progresses in Care Delivery with signed or closed divestments in all our Latin American markets, and closed divestments in Turkiye and of Cura Day Hospitals Group in Australia FY 2024 outlook confirmed BAD HOMBURG, Germany , May 7, 2024 /PRNewswire/ -- Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: "The first quarter of this year demonstrates that we are executing on our strategy as planned. Both segments expanded their respective margins compared to the prior year.
- 05/07/2024
|
Fresenius Medical beats earnings expectations, keeps outlook; shares sink
- Fresenius Medical Care beat first-quarter operating earnings expectations on Tuesday amid higher pricing and cost-cut savings, but the German company still maintained its profit outlook for 2024, sending its shares down in early trading.
- 05/07/2024
|
3 Medical Device Stocks With Solid Dividend Yield: CAH & Others
- Here we discuss three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.
- 04/11/2024
|
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
- Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
- 04/10/2024
|
Fresenius Medical (FMS) to Unveil Training on Augmented Reality
- Fresenius Medical (FMS) is launching digital learning elements with hands-on training for Kidney Replacement Therapy leveraging Augmented Reality.
- 03/25/2024
|
Fresenius Medical Care publishes 2023 joint Annual Report and Sustainability Report: Shaping the Future of Kidney Care
- Fresenius Medical Care delivers on commitments during a year of fundamental transformation Progress towards sustainability goals in key areas: patient satisfaction, diversity in management, climate target roadmap BAD HOMBURG, Germany , March 22, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today published its joint 2023 Annual Report and Non-financial Group Report, available digitally on the corporate website. Titled "Shaping the Future of Kidney Care," the report provides detailed information about Fresenius Medical Care's economic, social and environmental performance in 2023.
- 03/22/2024
|
Fresenius Medical Care launches "Augmented Reality" for training on Kidney Replacement Therapy device
- For the first time, Fresenius Medical Care develops and utilizes "Augmented Reality" (AR) to train medical staff in Intensive Care Units (ICUs) The new training application for ICU staff combines digital learning elements with real-life training on the Fresenius Medical Care Continuous Kidney Replacement Therapy system This learning experience reinforces initial training, a supplement to support new staff amidst the high fluctuation of specialists in intensive care nursing BAD HOMBURG, Germany , March 19, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, launches a new "Augmented Reality" (AR) application to make learning easier for nursing staff in Kidney Replacement Therapy in Intensive Care Units. The AR glasses, in combination with digital learning modules, allow nursing staff to learn how to use acute dialysis machines on site within the intensive care wards.
- 03/19/2024
|
Fresenius Medical Care appoints Jörg Häring as new Management Board member responsible for Legal, Compliance and Human Resources
- Effective June 1, the Legal, Compliance, and Human Resources functions will be combined in a new Management Board role Jörg Häring contributes his extensive expertise from the energy, industry, and healthcare sectors BAD HOMBURG, Germany , March 13, 2024 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has announced today the appointment of Jörg Häring (54) as its new Global Head of Legal, Compliance and Human Resources. Häring, who will join the company as a member of the Management Board, will start on June 1, 2024, and also assume the role of Labor Director.
- 03/13/2024
|
Fresenius Medical (FMS) Divests Assets to Optimize Portfolio
- Fresenius Medical's (FMS) latest asset divestments reflect a milestone in its portfolio optimization program and are likely to improve profitability.
- 03/11/2024
|
Fresenius Medical Care Achieves Next Milestone in Portfolio Optimization Program, Announcing Sale of Dialysis Clinics in Brazil, Colombia, Chile, Ecuador
- Divestment of assets includes four separate country transactions to DaVita Inc. for USD 300 million Transactions further reduce the Company`s clinic footprint in Latin America, following the exit from Argentina at the end of 2023 Expected to close throughout 2024 Proceeds to be used to reduce debt BAD HOMBURG, Germany , March 5, 2024 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the sale of its dialysis clinic networks in Brazil, Colombia, Chile and Ecuador to DaVita Inc. for a total transaction price of USD 300 million. Subject to regulatory approvals in Brazil, Colombia and Ecuador, the transactions represent another milestone in Fresenius Medical Care's portfolio optimization program, with each expected to close throughout 2024.
- 03/05/2024
|
Fresenius Medical (FMS) Q4 Earnings Beat, Operating Margin Up
- Fresenius Medical's (FMS) fourth-quarter revenues suffer due to unfavorable currency movement. However, the company?
- 02/21/2024
|
Fresenius Medical Care AG (FMS) Q4 2023 Earnings Call Transcript
- Fresenius Medical Care AG (FMS) Q4 2023 Earnings Call Transcript
- 02/20/2024
|
Fresenius Medical Care delivers on commitments in a year of fundamental transformation
- Revenue growth of 5% in 2023 driven by favorable business development Operating income1 growth of 15% exceeding top end of outlook range, due to business growth, FME25 savings ahead of plan and contributions from the Tricare settlement Successful execution on turnaround plan resulting in significant labor productivity improvements in Care Delivery and positive pricing in Care Enablement Several key divestments announced as part of the ongoing Portfolio Optimization Program Strong cash flow performance and net financial leverage ratio reduced Dividend of €1.19 per share proposed For 2024 continued revenue growth and accelerated operating income growth projected BAD HOMBURG, Germany, Feb. 20, 2024 /PRNewswire/ -- Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: "In 2023, we delivered on our commitments while we fundamentally transformed Fresenius Medical Care. Exceeding our upgraded financial outlook for the full year was the very successful finish to an extraordinary year.
- 02/20/2024
|
Fresenius Medical (FMS) Gets FDA Nod for New Hemodialysis System
- Fresenius Medical (FMS) receives an FDA nod for its new 5008X Hemodialysis System that aims to provide better dialysis therapy for kidney patients in the United States.
- 02/09/2024
|
Fresenius Medical Care Brings Industry-Leading Dialysis Therapy to Kidney Disease Patients in the U.S., demonstrating Global Leadership in Medical Device and Membrane Engineering Technologies
- Fresenius Medical Care (FME) receives U.S. Food and Drug Administration (FDA) 510(k) clearance of the company's 5008X Hemodialysis System. This will enable Fresenius Medical Care to offer the industry-leading, high-volume hemodiafiltration (Hv-HDF) dialysis therapy – already widely used in Europe – for people living with kidney diseases in the U.S. The 510(k) clearance allows the start of clinical evaluations and user-studies in the U.S., with a planned broad commercial launch of the 5008X Hemodialysis System in 2025.
- 02/08/2024
|
Fresenius Medical Care AG nominates Six Employee Representatives to the Supervisory Board
- BAD HOMBURG, Germany , Feb. 5, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has nominated six employee representatives as members of the company's Supervisory Board. Effective January 26, the competent court approved the company's application for the judicial appointment of the six employee representatives.
- 02/05/2024
|
Fresenius Medical (FMS) Divests Businesses to Optimize Portfolio
- Fresenius Medical (FMS) streamlines for success with three key divestments in 2023. These divestments are likely to impact operating income by EUR 500 million in the fourth quarter.
- 01/09/2024
|
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
- Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
- 12/20/2023
|
Fresenius plans to sell rehabilitation care clinics - FAZ
- Fresenius has hired UBS to manage the sale of its rehabilitation care clinic business as the German healthcare group focuses on core activities, Frankfurter Allgemeine Zeitung reported on Friday, citing financial sources.
- 12/08/2023
|
Fresenius Medical Care says data on 500,000 people stolen in U.S.
- Dialysis group Fresenius Medical Care said on Wednesday that data including medical records on 500,000 patients and former patients were stolen from a U.S. subsidiary's database.
- 12/06/2023
|
Fresenius Medical (FMS) Ups '23 Outlook After Legal Settlement
- Fresenius Medical (FMS) wins legal dispute against the U.S. government. Both revenues and operating income will benefit from the settlement agreement.
- 11/23/2023
|
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
- Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
- 11/22/2023
|
Who's afraid of Ozempic? From restaurants to package makers, companies work to calm investors' GLP-1 jitters.
- That's the message from many corporate executives who have lately been peppered with questions about how Wegovy, Ozempic and other drugs widely used for weight loss may impact their bottom line.
- 11/10/2023
|
Fresenius Medical (FMS) Q3 Earnings Miss, Operating Margin Up
- Fresenius Medical's (FMS) third-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.
- 11/03/2023
|
Fresenius Medical Care AG & Co. KGaA (FMS) Q3 2023 Earnings Call Transcript
- Fresenius Medical Care AG & Co. KGaA (FMS) Q3 2023 Earnings Call Transcript
- 11/02/2023
|
Top Medical Stocks to Buy Amid Recent Market Volatility
- Several Zacks Medical sector stocks were recently added to the Zacks Rank #1 (Strong Buy) list over the last week and should be viable options for investors during economic uncertainty as healthcare is always essential.
- 10/23/2023
|
Are Investors Undervaluing Fresenius Medical Care AG & Co. (FMS) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 10/20/2023
|
Here's Why You Should Retain Fresenius Medical (FMS) for Now
- Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
- 10/16/2023
|
Fresenius Medical: use of drugs like Ozempic has neutral effect on dialysis patient numbers
- Germany's Fresenius Medical Care , said that use of Ozempic, and other diabetes and weight-loss drugs of the same class, would have an overall neutral effect on how many patients will require the company's kidney dialysis services in the future.
- 10/12/2023
|
What other industries could weight loss drugs disrupt?
- Jared Holz, Mizuho health care sector strategist, joins the ‘Fast Money' traders to discuss Novo Nordisj's kidney trial outcomes and the impact of weight loss drugs on the health care sector.
- 10/11/2023
|
Why Dialysis Stocks Plunged Today
- Novo Nordisk shares rallied after it announced it will stop its FLOW trial nearly a year earlier than expected after positive feedback on interim data for semaglutide's ability to treat kidney disease. The news sent dialysis products and services providers plunging.
- 10/11/2023
|
Why Shares of Fresenius Medical Care Were Dropping on Wednesday
- Novo Nordisk ended a phase 3 trial early for Ozempic for preventing kidney disease because the trial was so successful. Fresenius and other dialysis-connected companies saw their shares fall on Wednesday.
- 10/11/2023
|
Ozempic Is Moving a Bunch of Stocks Wednesday Morning
- Markets were poised to move higher again on Wednesday morning. Shares of Novo Nordisk climbed on good news from a study of its drug Ozempic on kidney patients.
- 10/11/2023
|
Dialysis company shares plunge after Ozempic trial success vs. kidney trouble
- The trial success of Novo Nordisk's hit drug against kidney failure sent shares of a German kidney dialysis services firm plummeting on Wednesday.
- 10/11/2023
|
Here's Why You Should Retain Fresenius Medical (FMS) for Now
- Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
- 09/15/2023
|
Fresenius Medical's (FMS) New HHD Device to Increase Portability
- Fresenius Medical (FMS) gets FDA clearance for Versi HD with GuideMe Software, a portable, home hemodialysis device with an easy-to-use graphical interface providing easier training experiences.
- 08/24/2023
|
Fresenius Medical (FMS) Q2 Earnings and Revenues Beat Estimates
- Fresenius Medical's (FMS) second-quarter revenues benefit from strong performance across all segments. Inflationary pressure continues to improve, benefiting operating income.
- 08/03/2023
|
Fresenius Medical Care AG & Co. KGaA (FMS) Q2 2023 Earnings Call Transcript
- Fresenius Medical Care AG & Co. KGaA (NYSE:FMS ) Q2 2023 Earnings Conference Call August 2, 2023 9:30 AM ET Company Participants Dominik Heger - Head of Investor Relations Helen Giza - Chief Executive Officer and acting Chief Financial Officer Conference Call Participants Victoria Lambert - Berenberg Veronika Dubajova - Citi Richard Felton - Goldman Sachs Hassan Al-Wakeel - Barclays Oliver Metzger - ODDO BHF James Vane-Tempest - Jefferies International Limited Lisa Clive - A.D. Bernstein David Adlington - JPMorgan Christoph Gretler - Credit Suisse Falko Friedrichs - Deutsche Bank Hugo Solvet - BNP Paribas Exane Operator Ladies and gentlemen, thank you for standing by.
- 08/02/2023
|
Fresenius Medical Care: Heads Don't Roll - They Run
- Fresenius Medical Care is the world's leading full-service provider of dialysis care and benefits from the entire value chain thanks to its vertical integration. Despite its market-leading position, Fresenius has been a poor performer, with disappointing returns on invested capital and high turnover rates pointing to internal problems. The article takes a look at Fresenius' operational challenges and provides an update on the company's balance sheet against the backdrop of the current interest rate environment.
- 07/27/2023
|
Why Shares of Fresenius Medical Jumped This Week
- The move is meant to allow better and timelier decision-making. Fresenius operates dialysis facilities across the world.
- 07/14/2023
|
Fresenius Medical shareholders approve change in legal form
- Fresenius Medical Care said on Friday that shareholders voted with a 99.88% majority in favour of a change that will simplify its governance and make parent Fresenius SE a regular minority shareholder.
- 07/14/2023
|
Fresenius Medical Care shares drop on U.S. dialysis payment adjustment
- Shares in kidney dialysis group Fresenius Medical Care declined 1.7% at market open in Germany on Tuesday after a payment increase proposed by a major U.S. public health insurance body fell short of market expectations.
- 06/27/2023
|
Fresenius Medical Care: Other Stocks Still Better, But Upside Exists
- Fresenius Medical Care has shown some improvement in recent trends, but still faces headwinds and pressures in its markets. Analysts have consistently underestimated FMS's performance, and I think the company has a potential upside of 15% annually or 44% until 2025E. However, the native Fresenius ticker may be a better investment due to its diversification and better fundamentals, depending on your goals.
- 06/01/2023
|
Fresenius Medical (FMS) Q1 Earnings and Revenues Beat Estimates
- Fresenius Medical's (FMS) first-quarter revenues benefit from strong performances across all segments, especially the North America and Asia-Pacific regions. However, rising costs hurt margins.
- 05/10/2023
|
Francisco Garcia Parames' Cobas Funds 4th-Quater Letter
- Dear Investor:
- 02/22/2023
|
Fresenius Medical Care AG & Co. KGaA (FMS) Q4 2022 Earnings Call Transcript
- Fresenius Medical Care AG & Co. KGaA (NYSE:FMS ) Q4 2022 Earnings Conference Call February 22, 2023 9:30 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chair & Chief Executive Officer Conference Call Participants Graham Doyle - UBS Hassan Al-Wakeel - Barclays Oliver Metzger - ODDO BHF Christoph Gretler - CS Ed Ridley-Day - Redburn Lisa Clive - Bernstein James Vane-Tempest - Jefferies Victoria Lambert - Berenberg Falko Friedrichs - Deutsche Bank Robert Davies - Morgan Stanley Operator Ladies and gentlemen, thank you for standing by. I am Nicolas, your Chorus Call operator.
- 02/22/2023
|
Competition Coming For AbbVie's Blockbuster Humira
- It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.
- 02/16/2023
|
Fresenius: The Company Is Climbing, And I'm At 'Buy'
- I've been unfailingly bullish in the long-term on Fresenius - both the medical care, but also the main company headquartered in Germany. Fresenius has had an extremely tricky set of years, due to company challenges and what could be characterized as mismanagement (without being wrong).
- 01/06/2023
|
The 9 Best 4+% Yielding Dividend Aristocrats For 2023
- Dividend growth blue-chips are the best performing assets in history. There are no more dependable dividend growth blue-chips for the 2023 recession than dividends aristocrats.
- 12/31/2022
|
3 Stocks With Dividends of 3% or More to Buy on the Dip
- Three underpriced healthcare stocks provide an opportunity.
- 11/14/2022
|
Bear of the Day: Fresenius Medical (FMS)
- Profit estimates are moving in the wrong direction.
- 11/11/2022
|
Fresenius Medical's (FMS) Q3 Earnings and Revenues Top
- Fresenius Medical's (FMS) third-quarter revenues benefit from strong performance across all the geographic regions and segments. However, rising costs hurt margins.
- 11/02/2022
|
Fresenius Medical Care AG & Co. KGaA (FMS) Q3 2022 Earnings Call Transcript
- Fresenius Medical Care AG & Co. KGaA (NYSE:FMS ) Q3 2022 Earnings Conference Call October 31, 2022 10:30 AM ET Company Participants Dominik Heger - Head of Investor Relations Carla Kriwet - Chief Executive Officer & Chair of the Management Board Helen Giza - Deputy Chief Executive Officer, Chief Financial Officer & Chief Transformation Officer Conference Call Participants Tom Jones - Berenberg Graham Doyle - UBS James Vane-Tempest - Jefferies Hassan Al-Wakeel - Barclays Veronika Dubajova - Citi Oliver Metzger - ODDO BHF David Adlington - JPMorgan Robert Davies - Morgan Stanley Falko Friedrichs - Deutsche Bank Szegi Oezener - HSBC Operator Ladies and gentlemen, thank you for standing by. I'm Nathalie your Chorus Call operator.
- 10/31/2022
|
Fresenius Medical cuts outlook on slower recovery, rising costs
- Kidney dialysis provider Fresenius Medical Care (FMC) on Sunday revised down its forecast for 2022, expecting net income to decline this year, dragged down by rising labour costs and a slower than expected recovery in North America business.
- 10/30/2022
|
Fresenius: A Contrarian Opportunity Not Seen For 20 Years (Technical Analysis)
- Fresenius Medical Care has been a long-term laggard in its industry, losing over 70% in the past 5 years. The stock has seemingly bottomed and began to retrace on massive buy-side volume while breaking out of one of its most important short-term resistance.
- 10/27/2022
|
Fresenius Medical (FMS) Robust Product Portfolio Drives Growth
- Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
- 08/25/2022
|
Fresenius Medical's (FMS) Q2 Earnings Miss, Revenues Top
- Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across all the geographic regions and segments. However, rising costs hurt margins.
- 08/02/2022
|
Fresenius Medical Care: Best Time In 21 Years To Buy This High-Yield Dividend Aristocrat
- Fresenius isn't just an undervalued aristocrat, it's a Buffett-style anti-bubble "fat pitch" that could deliver 235% returns in the next five years. Even with the Pandemic-induced downturn, FMS is expected to grow at 12% CAGR through 2027.
- 07/30/2022
|
Fresenius now expects lower revenue, earnings in the second half, citing wage inflation and staff shortages in North America
- Shares of Fresenius Medical Care tumbled 13.7% in premarket trading on Thursday after telling investors to expect lower-than-expected revenue and net income in the second half of the year. The company, which provides kidney dialysis services, cited concerns about wage inflation and staff shortages in North America, higher inflation, and supply-chain disruptions.
- 07/28/2022
|
11 High-Yield Dividend Aristocrats Perfect For The Coming Recession
- Fears of a recession are mounting, with BAC and Deutsche Bank now forecasting a mild downturn in 2023. A recession could even begin by December 2022. Even without a recession Morgan Stanley is confident stocks have 10% lower to fall. If we get a mild recession, stocks could fall 25% more and in a severe recession, 35%.
- 07/20/2022
|
After Plunging 11.8% in 4 Weeks, Here's Why the Trend Might Reverse for Fresenius (FMS)
- The heavy selling pressure might have exhausted for Fresenius (FMS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 07/19/2022
|
Here's Why You Should Retain Fresenius Medical (FMS) Stock Now
- Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
- 07/19/2022
|
Fresenius (FMS) Faces Fraud Accusation From US Government
- The Department of Justice of the U.S. government files a civil complaint against Fresenius (FMS), accusing it of defrauding Medicare and other healthcare programs by billing for unnecessary procedures.
- 07/14/2022
|
Fresenius: Revisiting The Thesis - Still A Buy
- We'll take a look at Fresenius in order to determine if the company still represents a good investment opportunity. Given a recent share price weakness, it's not strange that some investors are wondering whether it's still investable.
- 06/19/2022
|
My, Oh, My 11 Incredible High-Yield Dividend Aristocrat Bear Market Buys
- This bear market is the 2nd worst start to the year in US stock market history. And cracks are beginning to form in credit markets that could potentially send stocks falling even lower in the coming months.
- 06/18/2022
|
Here's Why You Should Retain Fresenius Medical (FMS) Stock Now
- Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
- 06/14/2022
|
Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates
- Fresenius Medical's (FMS) first-quarter earnings benefit from strong performance across all the geographic regions and segments.
- 05/10/2022
|
Fresenius Medical Care AG & Co. (FMS) CEO Rice Powell on Q1 2022 Results - Earnings Call Transcript
- Fresenius Medical Care AG & Co. (NYSE:FMS ) Q1 2022 Earnings Conference Call May 4, 2022 9:30 AM ET Company Participants Dominik Heger - Head of IR Rice Powell - CEO Helen Giza - CFO Conference Call Participants Patrick Wood - Bank of America Oliver Metzger - ODDO BHF Tom Jones - Berenberg Graham Doyle - UBS David Adlington - JPMorgan Operator Ladies and gentlemen, thank you for standing by. I'm Natalie, your Chorus Call operator.
- 05/04/2022
|
Fresenius: The Upside Is Getting Bigger
- Fresenius is an interesting investment - certainly in part because it doesn't require an ADR, you can invest in the medical care wing with the symbol FMS. The company's organic growth has been slowed down, and the recovery for the company is likely in the future - but the upside is now close to 45%.
- 05/02/2022
|
Fresenius Medical (FMS) Launches Campaign to Boost Kidney Care
- Fresenius Medical's (FMS) My Reason campaign will help scientists understand genetic variations in patients with chronic kidney disease in a better way.
- 04/14/2022
|
Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y
- Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong performance across all the geographic regions and segments.
- 02/23/2022
|
Fresenius Medical Care AG & Co. KGaA. (FMS) CEO Rice Powell on Q4 2021 Results - Earnings Call Transcript
- Fresenius Medical Care AG & Co. KGaA. (FMS) CEO Rice Powell on Q4 2021 Results - Earnings Call Transcript
- 02/22/2022
|
Triple Your Retirement Income With These 6% Yielding Dividend Aristocrat Bargains
- Fear has returned to Wall Street, with the market falling 4% in a matter of days as the Wall of Worry starts to take its toll.
- 12/08/2021
|
Fresenius: The Selloff Is Creating A Buying Opportunity
- Fresenius: The Selloff Is Creating A Buying Opportunity
- 12/06/2021
|
Fresenius Medical's (FMS) New Dialyzer to Boost Patient Outcome
- Fresenius Medical's (FMS) latest dialyzer is expected to better serve dialysis patients because of its design.
- 12/01/2021
|
Fresenius Medical Care AG & Co. KGaA (FMS) CEO Rice Powell on Q3 2021 Results - Earnings Call Transcript
- Fresenius Medical Care AG & Co. KGaA (FMS) CEO Rice Powell on Q3 2021 Results - Earnings Call Transcript
- 11/02/2021
|
New Strong Sell Stocks for October 14th
- ARNC, BSET, FMS, OCUL, and PTGX have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2021.
- 10/14/2021
|
Ominous Death Cross Forms On Fresenius Medical Care's Chart
- If history is any guide, there may be trouble ahead for shares of Fresenius Medical Care(NYSE:FMS). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.
- 09/22/2021
|
Fresenius Medical's (FMS) Deal to Boost Home Dialysis in Japan
- Fresenius Medical (FMS) partners with JMS Co. Ltd. to provide innovative home dialysis therapies to the aging population in Japan to improve their wellbeing.
- 09/20/2021
|
Fresenius Medical Care Partners with JMS Co. Ltd. to Advance Home Dialysis Treatment in Japan
- HONG KONG--(BUSINESS WIRE)-- #Japan--Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has today announced a strategic distribution partnership with JMS Co. Ltd, a provider of medical devices and pharmaceuticals, in Japan. Under the agreement, JMS Co. Ltd. will distribute Fresenius Medical Care's innovative home dialysis therapies in the Japanese market, providing patients with a wider range of dialysis choices to suit their lifestyle, enh
- 09/17/2021
|
Fresenius SE Remains Unloved And Undervalued
- Fresenius SE Remains Unloved And Undervalued
- 09/13/2021
|
You Really Want To Know About Fresenius Medical Care
- Today, I'm considering becoming both a landlord and shareholder. Fresenius Medical Care-leased properties are trading at an average cap rate of 6.25% right now. This makes the investment thesis attractive.
- 08/28/2021
|
Fresenius Medical (FMS) Q2 Earnings Beat Estimates, Up Y/Y
- Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across the regions, EMEA, Asia Pacific and Latin America.
- 08/02/2021
|
Fresenius Medical Care AG & Co. KGaA (FMS) CEO Rice Powell on Q2 2021 Results - Earnings Call Transcript
- Fresenius Medical Care AG & Co. KGaA (FMS) CEO Rice Powell on Q2 2021 Results - Earnings Call Transcript
- 07/30/2021
|
Recap: Fresenius Medical Care Q2 Earnings
- Shares of Fresenius Medical Care (NYSE:FMS) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were down 31.82% over the past year to $0.45, which missed the estimate of $0.55.
- 07/30/2021
|
15 European Dividend Aristocrats to Diversify Your Portfolio
- Plenty of investors focus in on dividends, and dividend aristocrats, but if those investors only look in the U.S. they could be missing out. The post 15 European Dividend Aristocrats to Diversify Your Portfolio appeared first on InvestorPlace.
- 07/21/2021
|
Fresenius Medical's (FMS) Xenios Gets NMPA Nod for ECMO System
- Fresenius Medical (FMS) company receives expedited approval from NMPA permitting the Xenios AG's console and patient kits for ECMO therapy in China.
- 07/15/2021
|
Dividend Champions For July 2021
- Monthly update of the Dividend Champions List. 30 companies declared higher dividends in the past month, with an average increase of 12.17% over their previous payouts.
- 07/02/2021
|
Fresenius Medical's (FMS) Training Center to Boost Patient Care
- Fresenius Medical (FMS) inaugurates new training center in Korea to help in the improvement of patient care by offering comprehensive education programs for healthcare professionals.
- 06/29/2021
|
Fresenius Medical Care Supports Education for Healthcare Professionals in Korea With the Opening of Its First Training Center
- HONG KONG--(BUSINESS WIRE)-- #chronickidneydisease--Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, recently announced the grand opening of its first training center in Korea, to offer comprehensive education programs and share its knowledge and experience in renal care, critical care, and treatment strategies with healthcare professionals. The training programs and other events at the center will help strengthen the collective knowledge within the ind
- 06/27/2021
|
10 Different Stocks To Buy A 10-Year-Old 2nd Child
- This is a follow-up to my January 2018 article "10 First Stocks To Buy A 10-Year Old", reflecting on how choosing stocks for my 2nd 10-year old is different. 2nd children often look up to older siblings and feel some need to be different or competitive, and that shows in the stocks shown interest in.
- 05/27/2021
|
Fresenius: Q1 2021 Confirms The Positive Outlook
- Fresenius has reported 1Q21 - and the results confirm my positive outlook on the company. Since my initial article and investment, the position in my portfolio, invested in the DAX ticker, has appreciated nearly 21% excluding dividends.
- 05/12/2021
|
Fresenius Medical (FMS) Gains 1.1% Since Q1 Earnings Beat
- Fresenius Medical's (FMS) first-quarter earnings benefit from organic growth in Health Care Products segment, and performance in Asia Pacific.
- 05/12/2021
|
Fresenius Medical Care AG & Co. KGaA (FMS) CEO Rice Powell on Q1 2021 Results - Earnings Call Transcript
- Fresenius Medical Care AG & Co. KGaA (FMS) CEO Rice Powell on Q1 2021 Results - Earnings Call Transcript
- 05/09/2021
|
Fresenius Medical Care Appears To Be Fairly Valued
- Fresenius Medical Care is the world's leading dialysis company poised to profit from strong underlying tailwinds.
- 03/15/2021
|
Fresenius: An 8-20% Undervalued German Giant
- Fresenius is a massive $35B market cap company out of Germany in the healthcare sector. It's one of few German companies with an alternative listed on the NYSE. This makes investing in the company or segments far simpler than with ADRs and makes the company more potentially appealing for international investors.
- 03/09/2021
|
Fresenius Medical (FMS) Q4 Earnings Beat, Revenues Miss
- Fresenius Medical's (FMS) fourth-quarter earnings benefit from strength in Health Care Products segment, and performance across EMEA and Asia Pacific.
- 02/24/2021
|
Fresenius Medical Care AG & Co. KGaA (FMS) CEO Rice Powell on Q4 2020 Results - Earnings Call Transcript
- Fresenius Medical Care AG & Co. KGaA (FMS) CEO Rice Powell on Q4 2020 Results - Earnings Call Transcript
- 02/23/2021
|
Recap: Fresenius Medical Care Q4 Earnings
- Shares of Fresenius Medical Care (NYSE:FMS) rose 0.0% after the company reported Q4 results. Quarterly Results Earnings per share fell 50.00% year over year to $0.76, which missed the estimate of $0.77.
- 02/23/2021
|
Is Fresenius (FMS) Stock Undervalued Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 01/21/2021
|
4 MedTech Underperformers Poised for a Turnaround in 2021
- Here are some dirt-cheap MedTech value stocks which are expected to provide long-term gains in 2021.
- 01/21/2021
|
Fresenius Medical Care's Frenova enrolls patients in initiative to build world's largest genomic registry targeting kidney disease
- WALTHAM, Mass., Jan. 11, 2021 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for people with chronic kidney failure, announced today that the company's Frenova division has enrolled the first participants in its new initiative to develop the...
- 01/11/2021
|
Fresenius SE: Still Undervalued
- Fresenius SE: Still Undervalued
- 01/10/2021
|
Fresenius Medical Care Is A Global Market Leader And A Bargain
- Fresenius Medical Care might not be a ten-bagger in the next few years. Conversely, the stock currently offers a very good risk/reward ratio.
- 01/05/2021
|
Is Fresenius (FMS) a Solid Growth Stock? 3 Reasons to Think " Yes "
- Fresenius (FMS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 12/30/2020
|
Are Investors Undervaluing Fresenius (FMS) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 12/30/2020
|
German Dividend Aristocrats - The 2020 Update
- The German Dividend Aristocrats (GDA) have been updated - this is the 2020 version. There are 53 (-1) identified Dividend Aristocrats in Germany as of November 2020.
- 11/30/2020
|
Picks For October: 2 German And 2 U.S. Stocks
- Despite the correction, stocks - especially US stocks - are still trading at very high multiples and it is difficult to find bargains. Bayer and Fresenius are two German large-cap stocks that are trading at depressed levels.
- 10/30/2020
|
Fresenius Medical Care AG & Co. KGaA (FMS) CEO Robert Powell on Q3 2020 Results - Earnings Call Transcript
- Fresenius Medical Care AG & Co. KGaA (FMS) CEO Robert Powell on Q3 2020 Results - Earnings Call Transcript
- 10/30/2020
|
Fresenius Q3 2020 In-Depth Review
- Fresenius delivered very solid results despite the pandemic. Importantly, all guidance was confirmed.
- 10/29/2020
|
IPO Update: Outset Medical Finalizes Terms For IPO
- Outset Medical intends to raise $175 million in a U.S. IPO.
- 09/11/2020
|
August 2020 Dividend Portfolio Update
- Markets were racing to all-time highs in August fueled by technology stocks and the mega caps. I am continuing my monthly investment plans and suspiciously follow the massive rally in technology stocks.
- 09/05/2020
|
Bullish On Baxter: Cruising Along, Business As Usual; $90 Price Target Set
- Baxter continues to chug on slowly as it has done for the past 10 years, delivering ongoing value to shareholders.
- 08/28/2020
|
Outset Medical Begins U.S. IPO Rollout
- Outset Medical has filed to raise $100 million in an IPO, although the final figure may differ. The firm is commercializing an improved hemodialysis machine.
- 08/24/2020
|
Fresenius Medical Care: Dominant Dialysis Firm Is A Discounted Dividend Stock
- Fresenius Medical Care is the largest dialysis provider in the world. COVID-19 is unlikely to impact this firm over the long term.
- 08/21/2020
|
Fresenius Medical (FMS) Q2 Earnings & Revenues Top Estimates
- Fresenius Medical's (FMS) second-quarter earnings benefit from strong segmental performance.
- 08/05/2020
|
Fresenius Medical Care AG & Co. KGaA (FMS) Q2 2020 Earnings Call Transcript
- FMS earnings call for the period ending June 30, 2020.
- 07/31/2020
|
Fresenius Medical Care AG & Co. KGaA (FMS) CEO Robert Powell on Q2 2020 Results - Earnings Call Transcript
- Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Q2 2020 Earnings Conference Call July 30, 2020, 09:30 ET Company Participants Dominik Heger - EVP & Head, IR, Strategic Development & Communications Robert Powell - Chairman & CEO Helen Giza - CFO Conference Call Participants Patrick Wood - Bank of America Merrill Lynch Thomas Jones - Berenberg Veronika Dubajova - Goldman Sachs Group Oliver Metzger - Commerzbank James Vane-Tempest - Jefferies Michael Jungling - Morgan Stanley Christoph Gretler - Crédit Suisse Falko Friedrichs - Deutsche Bank Presentation Operator Ladies and gentlemen, thank you for standing by.
- 07/30/2020
|
Fresenius Medical Care AG & Co. KGaA 2020 Q2 - Results - Earnings Call Presentation
- The following slide deck was published by Fresenius Medical Care AG & Co. KGaA in conjunction with their 2020 Q2 earnings call..
- 07/30/2020
|
Fresenius beats second-quarter earnings forecasts, cuts 2020 outlook
- The group said its separately listed dialysis unit, Fresenius Medical Care, showed very strong earnings growth and exceptional cash flow in the quarter. For 2020, Fresenius expects adjusted net income change between a negative 4% and a positive 1%, and revenue growth in the range of 3% to 6%, compared to its previous forecast for growth between 1% to 5% and 4% to 7%, respectively, which did not account for the pandemic's effects. Fresenius' second-quarter net income came in at 410 million euros ($482.6 million), above analysts' average forecast of 398 million euros, according to a company-provided poll.
- 07/30/2020
|
June Portfolio Dividend Update
- June was a disappointing month in terms of dividend income, as it fell notably short Y/Y due to dividend cuts, suspensions and delays.
- 07/14/2020
|
Hedge Funds Are Souring On Fresenius Medical Care AG & Co. KGaA (FMS)
- We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
- 07/06/2020
|
Fresenius Medical Care: A Solid 2020 Will See Share Price Recapture 2018 Highs
- Fresenius looks to be significantly undervalued by the market. Based on FY19 EPS of $4.25 and a current price of $43, the company trades at a PE of 10x. The com
- 07/01/2020
|
Kiplinger's 'Most Reliable Dividend Stocks On Earth' Shows 16 Buys For July
- Kiplinger Investing, offering insights for investors online, compiled a Worlds Most Reliable list of 99 in October, 2018. Data updated 6/25/20 showed 19 whose y
- 06/28/2020
|
Why The German DAX30 Is Lagging
- The performance of the German DAX30 is poor since the GFC. It was beaten by the DJIA30 although the DAX30 is a performance index. Many companies are cyclical or
- 06/24/2020
|
Fresenius Medical Care (FMS) Presents At Goldman Sachs Global Healthcare Conference - Slideshow
- The following slide deck was published by Fresenius Medical Care AG & Co. KGaA in conjunction with this event.
- 06/16/2020
|
Stocks That Hit 52-Week Highs On Friday
|
Stocks That Hit 52-Week Highs On Tuesday
|
Stocks That Hit 52-Week Highs On Monday
|
Stocks That Hit 52-Week Highs On Friday
|
SunTrust Robinson Humphrey Maintains Buy on Fresenius Medical Care, Raises Price Target to $48
|
RBC Capital Sticks to Their Hold Rating for Fresenius Medical Care Corp.
- RBC Capital analyst Frank Morgan maintained a Hold rating on Fresenius Medical Care (NYSE:FMS) Corp. on Thursday, setting a price target of $42, which is approximately 6.90% above the present share price of $39.29.
- 05/18/2020
|
Is Fresenius Medical Care AG & Co. KGaA (ETR:FME) A Smart Pick For Income Investors?
- Is Fresenius Medical Care AG & Co. KGaA (ETR:FME) a good dividend stock? How can we tell? Dividend paying companies...
- 05/16/2020
|
Fresneius Boss Says Production Has Normalized In China And In US We Have Got Past The Worst
|
Nursing the World to Health: Celebrating Fresenius Kidney Care Nurses’ Contribution in Asia Pacific on International Nurses Day
- Today, on International Nurses Day, Fresenius Medical Care, the world’s leading provider of dialysis products and services, is celebrating the extraordinary contribution that its nurses make to the organization and wider community – every day, and particularly in the face of our current global health challenge.
- 05/12/2020
|
DCF Advisers, LLC Buys Berkshire Hathaway Inc, VanEck Vectors Gold Miners, Verizon ...
|
SunTrust Robinson Humphrey Maintains Buy on Fresenius Medical Care, Raises Price Target to $46
|
Fresenius Medical (FMS) Q1 Earnings Miss Estimates, Fall Y/Y
- Fresenius Medical's (FMS) first-quarter earnings benefit from strong segmental performance.
- 05/11/2020
|
Fresenius Medical Care AG & Co. KGaA (FMS) Q1 2020 Earnings Call Transcript
- Image source: The Motley Fool. Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)Q1 2020 Earnings CallMay 6, 2020, 9:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, thank you for standing by.
- 05/07/2020
|
Fresenius reports first-quarter net income beat on pandemic demand
- Healthcare companies worldwide have benefited from subsidies and increased demand as a result of the coronavirus crisis, but they have also faced new costs, including protective gear. Fresenius' first-quarter net income was 465 million euros ($503.97 million), above analysts' average forecast of 421.8 million euros, a Refinitiv poll found. "It is, however, too early to say with any certainty what impact COVID-19 will have on the company's full business year," Chief Executive Stephan Sturm said in a statement.
- 05/06/2020
|
European shares flat as mixed earnings, U.S.-China tensions weigh
- European shares opened little changed on Wednesday as a batch of mixed earnings reports and simmering U.S.-China tensions added to doubts about a swift economic recovery even as many countries eased lockdown measures. The pan-European STOXX 600 index was flat as losses in oil and gas sector, following a recent surge, offset gains in healthcare shares. The global mood also remained fragile as U.S. President Donald Trump again took aim at China, urging it to be transparent about the origins of the novel coronavirus outbreak.
- 05/06/2020
|
Earnings Scheduled For May 6, 2020
|
Best & Worst ADRs - Monday, April 5
|
Fresneius Shares Rebound From Low; Traders Circulate Unsourced/Unconfirmed Chatter Co. Received FDA Approval For Continuous Renal Replacement Therapy As Possible Treatment For Coronavirus
|
COVID-19 Impact on Medical Supplies Market - Exclusive Report by MarketsandMarkets™
- MarketsandMarkets™ published a report titled, "COVID-19 impact on Medical Supplies Market by Type (Intubation, Personal Protective Equipment, Infusion, Radiology, Wound Care Supplies), End User (Hospitals, Clinics) - Global Forecast to 2021". Based on their findings, the COVID-19 impact on
- 05/01/2020
|
Anthem (ANTM) Receives a Buy from RBC Capital
- RBC Capital analyst Frank Morgan maintained a Buy rating on Anthem (ANTM) today and set a price target of $319.00. The company's shares closed last
- 04/30/2020
|
Anthem (ANTM) Receives a Buy from RBC Capital
- RBC Capital analyst Frank Morgan maintained a Buy rating on Anthem (ANTM – Research Report) today and set a price
- 04/30/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Genocea Biosciences (GNCA), Chemed (CHE) and BioMarin
- 04/30/2020
|
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Deciphera Pharmaceuticals (DCPH) and Constellation Pharmaceuticals (CNST)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Universal Health (UHS), Deciphera Pharmaceuticals (DCPH)
- 04/30/2020
|
Analysts Offer Insights on Healthcare Companies: Universal Health (NYSE: UHS), Deciphera Pharmaceuticals (NASDAQ: DCPH) and Constellation Pharmaceuticals (NASDAQ: CNST)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Universal Health (
UHS
–
Research Report
), Deciphera Pharmaceuticals (
DCPH
–
Research Report
) and Constellation Pharmaceuticals (
CNST
–
Research Report
- 04/30/2020
|
New Report Reveals DaVita Engaged In "Lobbying Scheme" To Target Legislation Threatening Billing Loophole
- "...we thought it would be important to shed light on the ridiculous abuse of the medical system that continues under a cloak of legitimate lobbying efforts."
- 04/30/2020
|
Exiting Billion-Dollar Deals Over Coronavirus Spurs Big Court Fights
- (Bloomberg) -- A deal is a deal, except for a growing number of companies that agreed to buy assets before the Covid-19 pandemic sent markets plunging.Panicked executives already have launched a handful of legal battles that could blow up billions of dollars’ worth of merger and acquisition agreements
- 04/29/2020
|
Widen and Zee Jay Digital Form Strategic Partnership
- MADISON, Wis. and PROVIDENCE, R.I., April 28, 2020 -- Widen, a high-performing digital asset management (DAM) software company, and Zee Jay Digital, a marketing transformation.
- 04/28/2020
|
Berenberg Bank Analysts Give Fresenius SE & Co KGaA (FRA:FRE) a €59.50 Price Target
- Fresenius SE & Co KGaA (FRA:FRE) has been assigned a €59.50 ($69.19) price target by analysts at Berenberg Bank in a report released on Tuesday, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the stock. Berenberg Bank’s price objective would suggest a potential upside of 50.06% from the company’s previous close. FRE […]
- 04/28/2020
|
Fresenius SE price target lowered to EUR 51 from EUR 54 at Barclays FSNUY
- Fresenius SE price target lowered to EUR 51 from EUR 54 at Barclays Barclays FSNUY
- 04/27/2020
|
Fresenius Medical price target lowered to EUR 81 from EUR 84 at Barclays FMS
- Fresenius Medical price target lowered to EUR 81 from EUR 84 at Barclays Barclays FMS
- 04/27/2020
|
Analysts Are Bullish on These Financial Stocks: Herc Holdings (HRI), American Express (AXP)
- There's a lot to be optimistic about in the Financial sector as 3 analysts just weighed in on Herc Holdings (HRI), American Express (AXP) and Ehealth
- 04/27/2020
|
JPMorgan Chase & Co. Analysts Give Fresenius SE & Co KGaA (FRA:FRE) a €61.40 Price Target
- JPMorgan Chase & Co. set a €61.40 ($71.40) price objective on Fresenius SE & Co KGaA (FRA:FRE) in a research report released on Thursday, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock. A number of other research analysts have also commented on FRE. Sanford C. Bernstein set a €37.50 ($43.60) […]
- 04/26/2020
|
The Global Urology Devices Market is expected to grow from USD 28,095.40 Million in 2018 to USD 49,837.50 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 8.53%
- The Global Urology Devices Market is expected to grow from USD 28,095.40 Million in 2018 to USD 49,837.50 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 8.53%. Read the full report: https://www.reportlinker.com/p05871588/?utm_source=PRN The positioning of the Global Urology Devices
- 04/24/2020
|
Were Hedge Funds Right About United Airlines Holdings Inc (UAL)?
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 04/23/2020
|
The Zacks Analyst Blog Highlights: PayPal, International Business Machines, Fresenius Medical Care, Laboratory Corp. of America and Insulet
- The Zacks Analyst Blog Highlights: PayPal, International Business Machines, Fresenius Medical Care, Laboratory Corp. of America and Insulet
- 04/23/2020
|
The Zacks Analyst Blog Highlights: PayPal, International Business Machines, Fresenius Medical Care, Laboratory Corp. of America and Insulet
- The Zacks Analyst Blog Highlights: PayPal, International Business Machines, Fresenius Medical Care, Laboratory Corp. of America and Insulet
- 04/23/2020
|
The Zacks Analyst Blog Highlights: PayPal, International Business Machines, Fresenius Medical Care, Laboratory Corp. of America and Insulet
|
Top Stock Reports for PayPal, IBM & Fresenius Medical
- Top Stock Reports for PayPal, IBM & Fresenius Medical
- 04/22/2020
|
Top Stock Reports for PayPal, IBM & Fresenius Medical
- Today's Research Daily features new research reports on 16 major stocks, including PayPal (PYPL), International Business Machines (IBM) and Fresenius Medical Care (FMS).
- 04/22/2020
|
HCA Healthcare (HCA) Received its Third Buy in a Row
- After Barclays and Robert W. Baird gave HCA Healthcare (NYSE: HCA) a Buy rating last month, the company received another Buy, this time from RBC Capital.
- 04/22/2020
|
Fresenius Medical Care AG & Co.'s (FMS) Hold Rating Reaffirmed at Royal Bank of Canada
- Fresenius Medical Care AG & Co. (NYSE:FMS)‘s stock had its “hold” rating reaffirmed by equities research analysts at Royal Bank of Canada in a research report issued to clients and investors on Monday, AnalystRatings.com reports. They currently have a $42.00 price target on the stock. Royal Bank of Canada’s price objective suggests a potential upside […]
- 04/22/2020
|
Top Stock Reports for PayPal, IBM & Fresenius Medical
|
Cara Therapeutics Itching Drug Scratches Off Goals of Phase 3 Test
- A Cara Therapeutics drug developed to treat the severe itching experienced by patients receiving hemodialysis has met the main goal of a second late-stage
- 04/21/2020
|
VFMCRP and Cara Therapeutics announce positive results from global KALM-2 pivotal phase-III trial of KORSUVA™ injection in haemodialysis patients with Pruritus
- Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.02) Statisticall…
- 04/21/2020
|
Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma Announce Positive Results From Global KALM-2 Pivotal Phase 3 Trial of KORSUVATM Injection in Hemodialysis Patients with Pruritus
- Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean Worst Itching Intensity NRS score vs. placebo.
- 04/21/2020
|
VFMCRP and Cara Therapeutics announce positive results from global KALM-2 pivotal phase-III trial of KORSUVA™ injection in haemodialysis patients with Pruritus
- Regulatory News:
- 04/21/2020
|
Fresenius Medical Clears Key Benchmark, Hitting 80-Plus RS Rating
|
Brookdale (BKD) Receives a Hold from RBC Capital
- In a report released today, Frank Morgan from RBC Capital maintained a Hold rating on Brookdale (BKD), with a price target of $4.00. The company's shares
- 04/20/2020
|
Brookdale (BKD) Receives a Hold from RBC Capital
- In a report released today, Frank Morgan from RBC Capital maintained a Hold rating on Brookdale (BKD – Research Report),
- 04/20/2020
|
RBC Capital Remains a Buy on Surgery Partners (SGRY)
- In a report released today, Frank Morgan from RBC Capital maintained a Buy rating on Surgery Partners (SGRY), with a price target of $14.00. The company's
- 04/20/2020
|
RBC Capital Remains a Buy on Surgery Partners (SGRY)
- In a report released today,
Frank Morgan
from RBC Capital maintained a
Buy
rating on Surgery Partners (
SGRY
–
Research Report
), with a price target of
$14.00
. The company’s shares closed last Monday at $9.80.
According to
TipRanks.com
, Morgan is
- 04/20/2020
|
RBC Capital Remains a Buy on Select Medical (SEM)
- RBC Capital analyst Frank Morgan maintained a Buy rating on Select Medical (SEM) today and set a price target of $26.00. The company's shares closed last
- 04/20/2020
|
RBC Capital Remains a Buy on Select Medical (SEM)
- RBC Capital analyst
Frank Morgan
maintained a
Buy
rating on Select Medical (
SEM
–
Research Report
) today and set a price target of
$26.00
. The company’s shares closed last Monday at $16.00.
According to
TipRanks.com
, Morgan is a 5-star analyst wi
- 04/20/2020
|
Pennant Group (PNTG) Gets a Hold Rating from RBC Capital
- In a report released today, Frank Morgan from RBC Capital maintained a Hold rating on Pennant Group (PNTG), with a price target of $26.00. The company's
- 04/20/2020
|
Pennant Group (PNTG) Gets a Hold Rating from RBC Capital
- In a report released today,
Frank Morgan
from RBC Capital maintained a
Hold
rating on Pennant Group (
PNTG
–
Research Report
), with a price target of
$26.00
. The company’s shares closed last Friday at $19.12.
According to
TipRanks.com
, Morgan is a
- 04/20/2020
|
Acadia Healthcare (ACHC) Receives a Buy from RBC Capital
- In a report released today, Frank Morgan from RBC Capital maintained a Buy rating on Acadia Healthcare (ACHC), with a price target of $34.00. The
- 04/20/2020
|
Acadia Healthcare (ACHC) Receives a Buy from RBC Capital
- In a report released today, Frank Morgan from RBC Capital maintained a Buy rating on Acadia Healthcare (ACHC – Research
- 04/20/2020
|
RBC Capital Keeps Their Hold Rating on Fresenius Medical Care (FMS)
- In a report released today, Frank Morgan from RBC Capital maintained a Hold rating on Fresenius Medical Care (FMS), with a price target of $42.00. The
- 04/20/2020
|
RBC Capital Keeps Their Hold Rating on Fresenius Medical Care (FMS)
- In a report released today,
Frank Morgan
from RBC Capital maintained a
Hold
rating on Fresenius Medical Care (
FMS
–
Research Report
), with a price target of
$42.00
. The company’s shares closed last Monday at $36.04.
According to
TipRanks.com
, Mor
- 04/20/2020
|
The Ensign Group (ENSG) Gets a Buy Rating from RBC Capital
- In a report released today, Frank Morgan from RBC Capital maintained a Buy rating on The Ensign Group (ENSG), with a price target of $48.00. The company's
- 04/20/2020
|
The Ensign Group (ENSG) Gets a Buy Rating from RBC Capital
- In a report released today,
Frank Morgan
from RBC Capital maintained a
Buy
rating on The Ensign Group (
ENSG
–
Research Report
), with a price target of
$48.00
. The company’s shares closed last Monday at $36.88.
According to
TipRanks.com
, Morgan is
- 04/20/2020
|
RBC Capital Maintains Their Hold Rating on DaVita (DVA)
- RBC Capital analyst Frank Morgan maintained a Hold rating on DaVita (DVA) today and set a price target of $75.00. The company's shares closed last Monday
- 04/20/2020
|
RBC Capital Maintains Their Hold Rating on DaVita (DVA)
- RBC Capital analyst
Frank Morgan
maintained a
Hold
rating on DaVita (
DVA
–
Research Report
) today and set a price target of
$75.00
. The company’s shares closed last Monday at $77.20.
According to
TipRanks.com
, Morgan is a 5-star analyst with an a
- 04/20/2020
|
RBC Capital Keeps Their Buy Rating on Encompass Health (EHC)
- In a report released today, Frank Morgan from RBC Capital maintained a Buy rating on Encompass Health (EHC), with a price target of $84.00. The company's
- 04/20/2020
|
RBC Capital Keeps Their Buy Rating on Encompass Health (EHC)
- In a report released today,
Frank Morgan
from RBC Capital maintained a
Buy
rating on Encompass Health (
EHC
–
Research Report
), with a price target of
$84.00
. The company’s shares closed last Monday at $70.47.
According to
TipRanks.com
, Morgan is
- 04/20/2020
|
RBC Capital Keeps Their Buy Rating on Addus Homecare (ADUS)
- In a report released today, Frank Morgan from RBC Capital maintained a Buy rating on Addus Homecare (ADUS), with a price target of $98.00. The company's
- 04/20/2020
|
RBC Capital Keeps Their Buy Rating on Addus Homecare (ADUS)
- In a report released today,
Frank Morgan
from RBC Capital maintained a
Buy
rating on Addus Homecare (
ADUS
–
Research Report
), with a price target of
$98.00
. The company’s shares closed last Friday at $80.35.
According to
TipRanks.com
, Morgan is a
- 04/20/2020
|
LHC Group (LHCG) Gets a Buy Rating from RBC Capital
- In a report released today, Frank Morgan from RBC Capital maintained a Buy rating on LHC Group (LHCG), with a price target of $173.00. The company's
- 04/20/2020
|
Amedisys (AMED) Receives a Buy from RBC Capital
- RBC Capital analyst Frank Morgan maintained a Buy rating on Amedisys (AMED) today and set a price target of $218.00. The company's shares closed last
- 04/20/2020
|
Analysts' Opinions Are Mixed on These Healthcare Stocks: Chemed (CHE) and Regeneron (REGN)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Chemed (CHE) and Regeneron (REGN). Chemed (CHE) RBC Capital analyst
- 04/20/2020
|
Here's How P/E Ratios Can Help Us Understand Fresenius Medical Care AG & Co. KGaA (ETR:FME)
- The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll apply a basic P/E...
- 04/20/2020
|
Arden Trust Co Takes Position in Fresenius Medical Care AG & Co. (NYSE:FMS)
- Arden Trust Co bought a new stake in Fresenius Medical Care AG & Co. (NYSE:FMS) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 5,274 shares of the company’s stock, valued at approximately $173,000. Other hedge funds and other institutional investors also […]
- 04/19/2020
|
Fresenius Medical Care Holdings, Inc. -- Moody's announces completion of a periodic review of ratings of Fresenius Medical Care Holdings, Inc.
- Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Fresenius Medical Care Holdings, Inc. Frankfurt am Main, April 17, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Fresenius Medical Care Holdings, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
- 04/17/2020
|
Fresenius Medical Care US Finance III, Inc. -- Moody's announces completion of a periodic review of ratings of Fresenius Medical Care AG & Co. KGaA
- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Fresenius Medical Care AG & Co. KGaA and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
- 04/17/2020
|
Fresenius SE & Co KGaA (FRA:FRE) PT Set at €47.00 by Goldman Sachs Group
- Fresenius SE & Co KGaA (FRA:FRE) received a €47.00 ($54.65) price target from research analysts at Goldman Sachs Group in a report released on Friday, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the stock. Goldman Sachs Group’s price target would suggest a potential upside of 25.87% from the company’s current price. […]
- 04/17/2020
|
Fresenius Medical upgraded to Conviction Buy from Buy at Goldman Sachs FMS
- Fresenius Medical upgraded to Conviction Buy from Buy at Goldman Sachs Goldman Sachs FMS
- 04/17/2020
|
Fresenius Medical Care AG & Co. KGaA (ETR:FME) Given a €80.00 Price Target by Goldman Sachs Group Analysts
- Fresenius Medical Care AG & Co. KGaA (ETR:FME) has been given a €80.00 ($93.02) price objective by equities research analysts at Goldman Sachs Group in a research report issued to clients and investors on Wednesday, Borsen Zeitung reports. The brokerage currently has a “buy” rating on the stock. Goldman Sachs Group’s target price points to […]
- 04/17/2020
|
Analysts' Recent Ratings Changes for Fresenius Medical Care AG & Co. KGaA (FME)
- Fresenius Medical Care AG & Co. KGaA (ETR: FME) recently received a number of ratings updates from brokerages and research firms: 4/15/2020 – Fresenius Medical Care AG & Co. KGaA was given a new €80.00 ($93.02) price target on by analysts at Goldman Sachs Group Inc. They now have a “buy” rating on the stock. […]
- 04/17/2020
|
Outlook on the Worldwide Dialysis Market to 2026 - Featuring Asahi Kasei, B.Braun Melsungen & Baxter International Among Others - ResearchAndMarkets.com
- The "Global Dialysis Market, Dialysis Patients, by Type (Hemodialysis, Peritoneal Dialysis), Product & Services (Equipments, Consumables, Services), End-Use, Regions, Company Analysis, Recent Developments - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
- 04/16/2020
|
Head to Head Contrast: Glaukos (NYSE:GKOS) & FRESENIUS SE &/S (NYSE:FSNUY)
- FRESENIUS SE &/S (OTCMKTS:FSNUY) and Glaukos (NYSE:GKOS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership. Volatility & Risk FRESENIUS SE &/S has a beta of 1.29, indicating that its share price […]
- 04/16/2020
|
The Global Nephrology Devices Market is expected to grow from USD 11,952.37 Million in 2019 to USD 17,226.74 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.28%
- New York, April 15, 2020 -- Reportlinker.com announces the release of the report "Nephrology Devices Market Research Report by Device - Global Forecast to 2025" -.
- 04/15/2020
|
Global Dialysis Market (2015 to 2026) - Dialysis Patients, by Type, Product & Services, End-Use, Regions, Company Analysis & Recent Developments
- Dublin, April 15, 2020 -- The "Global Dialysis Market, Dialysis Patients, by Type (Hemodialysis, Peritoneal Dialysis), Product & Services (Equipments, Consumables,.
- 04/15/2020
|
The Global Nephrology Device Market is expected to grow from USD 11,952.37 Million in 2019 to USD 17,226.74 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.28%
- New York, April 13, 2020 -- Reportlinker.com announces the release of the report "Nephrology Device Market Research Report by Device - Global Forecast to 2025" -.
- 04/13/2020
|
SunTrust Robinson Humphrey Maintains Buy on Fresenius Medical Care, Lowers Price Target to $42
|
Analysts Offer Insights on Services Companies: WW Grainger (GWW), Alibaba (BABA) and Community Health (CYH)
- Companies in the Services sector have received a lot of coverage today as analysts weigh in on WW Grainger (GWW), Alibaba (BABA) and Community Health
- 04/13/2020
|
RBC Capital Sticks to Their Buy Rating for Tenet Healthcare (THC)
- RBC Capital analyst Frank Morgan maintained a Buy rating on Tenet Healthcare (THC) today and set a price target of $26.00. The company's shares closed
- 04/13/2020
|
RBC Capital Sticks to Its Buy Rating for Universal Health (UHS)
- RBC Capital analyst Frank Morgan maintained a Buy rating on Universal Health (UHS) today and set a price target of $145.00. The company's shares closed
- 04/13/2020
|
Analysts' Top Healthcare Picks: Fortress Biotech (FBIO), Sarepta Therapeutics (SRPT)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Fortress Biotech (FBIO), Sarepta Therapeutics (SRPT) and
- 04/13/2020
|
Analysts’ Top Healthcare Picks: Fortress Biotech (FBIO), Sarepta Therapeutics (SRPT)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Fortress Biotech (
FBIO
–
Research Report
), Sarepta Therapeutics (
SRPT
–
Research Report
) and HCA Healthcare (
HCA
–
Research Report
) with bullish sent
- 04/13/2020
|
RBC Capital Maintains Their Buy Rating on Cigna (CI)
- In a report issued on April 9, Frank Morgan from RBC Capital maintained a Buy rating on Cigna (CI), with a price target of $249.00. The company's shares
- 04/13/2020
|
Anthem (ANTM) Gets a Buy Rating from RBC Capital
- RBC Capital analyst Frank Morgan maintained a Buy rating on Anthem (ANTM) on April 9 and set a price target of $319.00. The company's shares closed last
- 04/13/2020
|
UnitedHealth (UNH) Receives a Buy from RBC Capital
- In a report issued on April 9, Frank Morgan from RBC Capital maintained a Buy rating on UnitedHealth (UNH), with a price target of $332.00. The company's
- 04/13/2020
|
Humana (HUM) Gets a Hold Rating from RBC Capital
- In a report issued on April 9, Frank Morgan from RBC Capital maintained a Hold rating on Humana (HUM), with a price target of $345.00. The company's
- 04/13/2020
|
Fresenius Medical Care AG & Co. KGaA (ETR:FME) PT Set at €80.00 by Goldman Sachs Group
- Fresenius Medical Care AG & Co. KGaA (ETR:FME) has been assigned a €80.00 ($93.02) price objective by investment analysts at Goldman Sachs Group in a note issued to investors on Thursday, Borsen Zeitung reports. The firm presently has a “buy” rating on the stock. Goldman Sachs Group’s price objective points to a potential upside of […]
- 04/11/2020
|
Global IT Solution for Dialysis Market to Surpass US$ 5,694.9 Million by 2027, Says CMI
- SEATTLE, April 10, 2020 -- According to Coherent Market Insights, the global IT solution for dialysis market is estimated to be valued at US$ 3,335.8 million in 2019 and is.
- 04/10/2020
|
Specialty Physicians Predict More Pain Ahead in the Battle Against COVID-19
- Special Report: Multi-Specialty Impact of COVID-19 is an independent project being run by Spherix to assess the impact of the COVID-19 crisis on dermatologists, gastroenterologists, nephrologists, neurologists, and rheumatologists. Each Friday, over 250 specialists are surveyed about impact, concerns
- 04/09/2020
|
DZ Bank Reiterates Buy Rating for Fresenius SE & Co KGaA (FRA:FRE)
- Fresenius SE & Co KGaA (FRA:FRE)‘s stock had its “buy” rating restated by analysts at DZ Bank in a research note issued to investors on Tuesday, Borsen Zeitung reports. Other analysts have also issued reports about the company. Sanford C. Bernstein set a €37.50 ($43.60) price objective on Fresenius SE & Co KGaA and gave […]
- 04/09/2020
|
LHC Group (LHCG) Receives a Buy from RBC Capital
- RBC Capital analyst Frank Morgan maintained a Buy rating on LHC Group (LHCG) yesterday and set a price target of $180.00. The company's shares closed last
- 04/08/2020
|
Analysts Are Bullish on These Financial Stocks: Lendingtree (TREE), Ehealth (EHTH)
- There's a lot to be optimistic about in the Financial sector as 3 analysts just weighed in on Lendingtree (TREE), Ehealth (EHTH) and GooseHead Insurance
- 04/08/2020
|
Analysts Are Bullish on These Financial Stocks: Lendingtree (TREE), Ehealth (EHTH)
- There’s a lot to be optimistic about in the Financial sector as 3 analysts just weighed in on Lendingtree (TREE
- 04/08/2020
|
WeWork Directors Sue SoftBank Over Decision to Abandon Deal
- (Bloomberg) — Two independent WeWork directors sued SoftBank Group Corp., its biggest shareholder, after the Japanese investor scrapped a $3 billion deal to buy stock from ex-Chief Executive …
- 04/07/2020
|
March 2020 Dividend Portfolio Update: A Month To Remember
- March 2020 is surely a month to remember, not just for a week, a month or a year but forever. Cash has proven to be king and I have mostly run out of it just wh
- 04/07/2020
|
Berenberg Bank Reiterates €59.50 Price Target for Fresenius SE & Co KGaA (FRA:FRE)
- Berenberg Bank set a €59.50 ($69.19) price target on Fresenius SE & Co KGaA (FRA:FRE) in a research note published on Friday, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock. A number of other research firms also recently weighed in on FRE. Morgan Stanley set a €51.00 ($59.30) price target […]
- 04/06/2020
|
Continuous Renal Replacement Therapy Market to Exhibit 7.5% CAGR; High Incidence of Hypertension to Propel Growth, says Fortune Business Insights™
- Pune, April 06, 2020 -- The global continuous renal replacement therapy (CRRT) market is set to be positively impacted by rising technological advancements by renowned acute.
- 04/06/2020
|
Continuous Renal Replacement Therapy Market to Exhibit 7.5% CAGR; High Incidence of Hypertension to Propel Growth, says Fortune Business Insights™
- Key Companies Covered in the CRRT Market Research Report are NIPRO Corporation, NxStage Medical, Inc., Baxter International Inc., Medtronic plc, Fresenius Medical Care AG & Co. KGaA, Toray Medical Co., Ltd., B.
- 04/06/2020
|
The Global Home Healthcare Market is expected to grow from USD 216,920.28 Million in 2018 to USD 364,389.47 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.69%
- New York, April 03, 2020 -- Reportlinker.com announces the release of the report "Global Home Healthcare Market - Premium Insight, Competitive News Feed Analysis, Company.
- 04/03/2020
|
Fresenius SE & Co KGaA (FRA:FRE) PT Set at €37.00 by Jefferies Financial Group
- Fresenius SE & Co KGaA (FRA:FRE) has been assigned a €37.00 ($43.02) price objective by stock analysts at Jefferies Financial Group in a note issued to investors on Wednesday, Borsen Zeitung reports. The brokerage currently has a “neutral” rating on the stock. Jefferies Financial Group’s target price would indicate a potential upside of 8.50% from […]
- 04/03/2020
|
DaVita to hire 15,000 employees across U.S. in 2020
- DaVita's Denver headquarters.
- 04/02/2020
|
EU will avoid medicine shortage, industry chief says
- PARIS — European Union countries will have access to the medicines they need to care for coronavirus sufferers, the bloc’s industry chief Thierry Breton said on Thursday, adding pharmac…
- 04/02/2020
|
EU will avoid medicine shortage, industry chief says
- European Union countries will have access to the medicines they need to care for coronavirus sufferers, the bloc's industry chief Thierry Breton said on Thursday, adding pharmaceutical companies were doubling production to address shortages. The coronavirus pandemic has placed a huge strain on hospitals
- 04/02/2020
|
Global Home Healthcare Market Expected to Grow with a CAGR of 9% During the Period, 2019-2024 - ResearchAndMarkets.com
- The "Home Healthcare Market Report: Trends, Forecast and Competitive Analysis" report has been added to ResearchAndMarkets.com's offering.
- 04/01/2020
|
DaVita collaborates with competitor on plan to serve dialysis patients during COVID-19
- DaVita's Denver headquarters.
- 04/01/2020
|
Fresenius Medical Care working with dialysis providers in U.S. to tackle coronavirus
- BERLIN — Fresenius Medical Care (FMC) on Wednesday said it was working with other dialysis providers to provide care in isolation for people with kidney problems in the United States who are …
- 04/01/2020
|
Fresenius Medical Care working with dialysis providers in U.S. to tackle coronavirus
- Fresenius Medical Care (FMC) on Wednesday said it was working with other dialysis providers to provide care in isolation for people with kidney problems in the United States who are or may be infected with coronavirus. FMC, the world's largest kidney dialysis provider, said it was collaborating
- 04/01/2020
|
Focus on Patient Care Brings Industry Together to Fight Crisis
- Fresenius Medical Care North America (FMCNA) and DaVita Inc. (DVA) today announced a collaboration in response to Novel Coronavirus (COVID-19), which aims to support the broader kidney care community by offering isolation capacity for dialysis patients who are or may be COVID-19 positive.
- 03/31/2020
|
How to Find the Best Stocks in a Bear Market
- Sometimes a good stock can go bad and vice versa. Here's a simple way to keep up on the latest upgrades and downgrades.
- 03/31/2020
|
CytoSorb Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care
- CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its CytoSorb cytokine adsorber has been
- 03/31/2020
|
Edited Transcript of CRMD earnings conference call or presentation 16-Mar-20 8:30pm GMT
- Q4 2019 CorMedix Inc Earnings Call
- 03/30/2020
|
Fresenius SE & Co KGaA (FRA:FRE) Given a €37.50 Price Target at Sanford C. Bernstein
- Fresenius SE & Co KGaA (FRA:FRE) has been given a €37.50 ($43.60) price objective by analysts at Sanford C. Bernstein in a research report issued on Monday, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the stock. Sanford C. Bernstein’s price target would suggest a potential upside of 7.53% from the stock’s […]
- 03/30/2020
|
Stocks With Rising Relative Strength: Fresenius Medical
|
Edited Transcript of CTSO.OQ earnings conference call or presentation 5-Mar-20 9:45pm GMT
- Full Year 2019 Cytosorbents Corp Earnings Call
- 03/28/2020
|
Edited Transcript of AKBA earnings conference call or presentation 10-Mar-20 1:00pm GMT
- Q4 2019 Akebia Therapeutics Inc Earnings Call
- 03/26/2020
|
Fresenius SE & Co KGaA (FRA:FRE) PT Set at €59.50 by Berenberg Bank
- Fresenius SE & Co KGaA (FRA:FRE) has been assigned a €59.50 ($69.19) price target by analysts at Berenberg Bank in a research report issued to clients and investors on Thursday, Borsen Zeitung reports. The brokerage currently has a “buy” rating on the stock. Berenberg Bank’s price target indicates a potential upside of 74.28% from the […]
- 03/26/2020
|
Fresenius SE & Co KGaA (FRA:FRE) Earns "Neutral" Rating from UBS Group
- UBS Group reiterated their neutral rating on shares of Fresenius SE & Co KGaA (FRA:FRE) in a report issued on Monday morning, Borsen Zeitung reports. A number of other equities research analysts also recently issued reports on the company. Credit Suisse Group set a €55.00 ($63.95) price target on Fresenius SE & Co KGaA and […]
- 03/26/2020
|
Fresenius SE & Co KGaA (FRA:FRE) Rating Reiterated by DZ Bank
- Fresenius SE & Co KGaA (FRA:FRE)‘s stock had its “buy” rating reiterated by research analysts at DZ Bank in a report released on Monday, Borsen Zeitung reports. A number of other research analysts have also recently issued reports on FRE. UBS Group set a €47.00 ($54.65) target price on Fresenius SE & Co KGaA and […]
- 03/25/2020
|
Imagine Owning Fresenius Medical Care KGaA (ETR:FME) And Wondering If The 27% Share Price Slide Is Justified
- These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. By comparison...
- 03/23/2020
|
Fresenius SE & Co KGaA (FRA:FRE) PT Set at €62.00 by Kepler Capital Markets
- Fresenius SE & Co KGaA (FRA:FRE) has been assigned a €62.00 ($72.09) price objective by equities researchers at Kepler Capital Markets in a research report issued to clients and investors on Friday, Borsen Zeitung reports. The brokerage currently has a “buy” rating on the stock. Kepler Capital Markets’ price target would suggest a potential upside […]
- 03/22/2020
|
Edited Transcript of CARA earnings conference call or presentation 27-Feb-20 9:30pm GMT
- Q4 2019 Cara Therapeutics Inc Earnings Call
- 03/20/2020
|
Stocks That Hit 52-Week Lows On Friday
|
Top Stock Reports for Walmart, NVIDIA & AstraZeneca
- Top Stock Reports for Walmart, NVIDIA & AstraZeneca
- 03/19/2020
|
American Finance Trust Comments on COVID-19
- American Finance Trust, Inc. (Nasdaq: AFIN) ("AFIN" or the "Company") today issued the following statement regarding the on-going COVID-19 pandemic.
- 03/19/2020
|
Analysts Offer Insights on Services Companies: Advance Auto Parts (AAP), Genesis Healthcare (GEN) and Stericycle (SRCL)
- Companies in the Services sector have received a lot of coverage today as analysts weigh in on Advance Auto Parts (AAP), Genesis Healthcare (GEN) and
- 03/18/2020
|
Fresenius Medical Hits 80-Plus Relative Strength Rating Benchmark
|
Hedge Funds Started Selling ResMed Inc. (RMD) Before Coronavirus
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 03/16/2020
|
Hedge Funds Started Selling American Water Works Company (AWK) Before Coronavirus
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 03/16/2020
|
Hedge Funds Have Never Been This Bullish On Fresenius Medical Care AG & Co. (FMS)
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 03/16/2020
|
Shares of several healthcare companies are trading lower as the coronavirus outbreak continues to cause economic disruption around the globe, leading to a steep selloff in equities across sectors.
|
Fresenius SE & Co KGaA (FRA:FRE) PT Set at €62.00 by Kepler Capital Markets
- Fresenius SE & Co KGaA (FRA:FRE) has been assigned a €62.00 ($72.09) price objective by Kepler Capital Markets in a research note issued to investors on Friday, Borsen Zeitung reports. The firm presently has a “buy” rating on the stock. Kepler Capital Markets’ target price suggests a potential upside of 97.80% from the company’s current […]
- 03/15/2020
|
Edited Transcript of GALNA.S earnings conference call or presentation 12-Mar-20 1:00pm GMT
- Full Year 2019 Vifor Pharma AG Earnings Call
- 03/12/2020
|
The Kidney Kid Superhero Initiative Goes International on World Kidney Day
- Fresenius Medical Care, the world’s leading provider of dialysis products and services, has today announced the international and digital expansion of its highly successful Asia Pacific-wide Corporate Social Responsibility (CSR) initiative, The Kidney Kid superhero. This colorful character takes children on a series of adventures to learn more about their ‘super organ’ kidneys and how to keep them healthy. The expansion of this initiative comes on World Kidney Day, which in 2020, is calling on everyone to advocate for concrete measures in every country to promote and advance kidney disease prevention.
- 03/12/2020
|
Fresenius SE & Co KGaA (FRA:FRE) Given a €42.90 Price Target by Sanford C. Bernstein Analysts
- Fresenius SE & Co KGaA (FRA:FRE) has been assigned a €42.90 ($49.88) price target by equities researchers at Sanford C. Bernstein in a research report issued on Tuesday, Borsen Zeitung reports. The brokerage currently has a “neutral” rating on the stock. Sanford C. Bernstein’s target price suggests a potential upside of 19.10% from the stock’s […]
- 03/12/2020
|
Edited Transcript of III.OQ earnings conference call or presentation 11-Mar-20 1:00pm GMT
- Q4 2019 Information Services Group Inc Earnings Call
- 03/11/2020
|
Should You Avoid Dollar Tree, Inc. (DLTR)?
- Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published this article and predicted that US stocks will go down by at least 20% in the next 3-6 months. We also told you to short the market ETFs and buy long-term bonds. Investors who agreed with
- 03/11/2020
|
Hedge Funds Flocked Into United Airlines (UAL) At The Wrong Time
- Coronavirus is probably the 1 concern in investors' minds right now. It should be. We estimate that COVID-19 will kill around 5 million people worldwide and there is a 3.3% probability that Donald Trump will die from the new coronavirus (read the details). In these volatile markets we scrutinize
- 03/10/2020
|
RBC Capital Reaffirms Their Hold Rating on Pennant Group (PNTG)
- RBC Capital analyst Frank Morgan maintained a Hold rating on Pennant Group (PNTG) on March 6 and set a price target of $28.00. The company's shares closed
- 03/09/2020
|
RBC Capital Reaffirms Their Hold Rating on Pennant Group (PNTG)
- RBC Capital analyst
Frank Morgan
maintained a
Hold
rating on Pennant Group (
PNTG
–
Research Report
) on March 6 and set a price target of
$28.00
. The company’s shares closed last Monday at $22.80.
According to
TipRanks.com
, Morgan is a 5-star anal
- 03/09/2020
|
Analysts Conflicted on These Financial Names: Ehealth (EHTH), TriplePoint Venture Growth (TPVG) and Essex Property (ESS)
- Companies in the Financial sector have received a lot of coverage today as analysts weigh in on Ehealth (EHTH), TriplePoint Venture Growth (TPVG) and
- 03/09/2020
|
Second-Order Effects Of The Coronavirus Panic
- While everybody is staring at confirmed cases climbing globally, more important long-term effects of the coronavirus outbreak are in the making. Investors that
- 03/09/2020
|
February 2020 Dividend Portfolio Update
- February generated $347 in dividend income, up $32% sequentially and +25% Y/Y. Projected 12M forward income has hit $3,800, with Gifted Working Time amounting t
- 03/09/2020
|
Fresenius SE & Co KGaA (FRA:FRE) Rating Reiterated by DZ Bank
- Fresenius SE & Co KGaA (FRA:FRE)‘s stock had its “buy” rating restated by investment analysts at DZ Bank in a research note issued on Friday, Borsen Zeitung reports. Other analysts also recently issued reports about the company. Warburg Research set a €63.00 ($73.26) target price on Fresenius SE & Co KGaA and gave the stock […]
- 03/08/2020
|
The Best Biotech Stocks To Buy Now
- Healthcare is a top sector in our weekly ranking. Why Ironwood Pharmaceuticals and ACADIA Pharmaceuticals are among the highest-rated biotech companies in our u
- 03/06/2020
|
Fresenius Medical price target lowered to EUR 89.70 from EUR 89.95 at Berenberg FMS
- Fresenius Medical price target lowered to EUR 89.70 from EUR 89.95 at Berenberg Berenberg FMS
- 03/05/2020
|
Edited Transcript of ANIP earnings conference call or presentation 27-Feb-20 3:30pm GMT
- Q4 2019 ANI Pharmaceuticals Inc Earnings Call
- 03/04/2020
|
Nephrology Devices Market to Generate $16.42 Billion by 2026: Allied Market Research
- Portland, OR, March 04, 2020 -- The Nephrology Devices Industry generated $12.51 billion in 2019 and is estimated to garner $16.42 billion by 2026, growing at a CAGR of 4.0%.
- 03/04/2020
|
Global Urological Catheters Industry
- New York, March 04, 2020 -- Reportlinker.com announces the release of the report "Global Urological Catheters Industry" - https://www.reportlinker.com/p05151475/?utm_source=GNW.
- 03/04/2020
|
LHC Group (LHCG) Gets a Buy Rating from RBC Capital
- RBC Capital analyst Frank Morgan maintained a Buy rating on LHC Group (LHCG) on March 1 and set a price target of $180.00. The company's shares closed
- 03/04/2020
|
Analysts Are Bullish on These Services Stocks: Acadia Healthcare (ACHC), American Tower (AMT)
- There's a lot to be optimistic about in the Services sector as 3 analysts just weighed in on Acadia Healthcare (ACHC), American Tower (AMT) and AutoZone
- 03/04/2020
|
Fresenius SE & Co KGaA's (FRE) Neutral Rating Reaffirmed at Barclays
- Barclays restated their neutral rating on shares of Fresenius SE & Co KGaA (FRA:FRE) in a research report report published on Tuesday, Borsen Zeitung reports. Several other research analysts have also recently issued reports on FRE. Goldman Sachs Group set a €53.00 ($61.63) target price on shares of Fresenius SE & Co KGaA and gave […]
- 03/04/2020
|
Fresenius SE & Co KGaA (FRA:FRE) Given a €51.00 Price Target by Morgan Stanley Analysts
- Fresenius SE & Co KGaA (FRA:FRE) has been given a €51.00 ($59.30) target price by equities researchers at Morgan Stanley in a report issued on Monday, Borsen Zeitung reports. The firm presently has a “neutral” rating on the stock. Morgan Stanley’s target price would suggest a potential upside of 20.23% from the stock’s previous close. […]
- 03/04/2020
|
Fresenius Medical Reaches 80-Plus Relative Strength Rating Benchmark
|
Fresenius SE & Co KGaA (FRA:FRE) Receives Average Recommendation of "Buy" from Analysts
- Fresenius SE & Co KGaA (FRA:FRE) has been assigned a consensus recommendation of “Buy” from the sixteen research firms that are presently covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month price objective among […]
- 03/01/2020
|
Chemotherapy Devices Market Analysis - New Opportunities Explored, High CAGR & ROI Anticipated Till 2026: Radiant Insights, Inc.
- The global chemotherapy devices market is was valued at 152.80 million USD in 2017 and is anticipated to grow at a significant rate during the forecast period. Chemotherapy devices are used to slow down or kill the growth of cancer cells. The drugs generally used are called cytotoxics and are often obtained
- 02/27/2020
|
Akorn Provides Fourth Quarter and Full Year 2019 Results
- LAKE FOREST, Ill., Feb. 26, 2020 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced its financial results for the quarter and year ended.
- 02/26/2020
|
Fresenius SE & Co KGaA (FRA:FRE) Given a €58.00 Price Target by Nord/LB Analysts
- Nord/LB set a €58.00 ($67.44) price target on Fresenius SE & Co KGaA (FRA:FRE) in a research note released on Tuesday morning, Borsen Zeitung reports. The firm currently has a buy rating on the stock. Several other brokerages also recently issued reports on FRE. HSBC set a €53.00 ($61.63) price target on shares of Fresenius […]
- 02/26/2020
|
Analysts Offer Insights on Services Companies: Abercrombie Fitch (ANF), Caesars (CZR) and Fresenius Medical Care (FMS)
- Analysts fell to the sidelines weighing in on Abercrombie Fitch (ANF), Caesars (CZR) and Fresenius Medical Care (FMS) with neutral ratings, indicating
- 02/26/2020
|
Fresenius Medical Care AG & Co. KGaA (ETR:FME) Delivered A Better ROE Than Its Industry
- One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
- 02/26/2020
|
Stocks Showing Improved Relative Strength: Fresenius Medical
|
Fresenius SE & Co KGaA (FRA:FRE) Given a €54.00 Price Target at Independent Research
- Fresenius SE & Co KGaA (FRA:FRE) has been assigned a €54.00 ($62.79) price objective by stock analysts at Independent Research in a research report issued to clients and investors on Monday, Borsen Zeitung reports. The brokerage presently has a “neutral” rating on the stock. Independent Research’s price objective suggests a potential upside of 11.94% from […]
- 02/24/2020
|
Fresenius SE & Co KGaA (FRA:FRE) Given a €55.00 Price Target by Credit Suisse Group Analysts
- Credit Suisse Group set a €55.00 ($63.95) price objective on Fresenius SE & Co KGaA (FRA:FRE) in a research report sent to investors on Friday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock. A number of other brokerages have also commented on FRE. JPMorgan Chase & Co. set a […]
- 02/24/2020
|
Deutsche Bank Reiterates "€65.00" Price Target for Fresenius SE & Co KGaA (FRA:FRE)
- Deutsche Bank set a €65.00 ($75.58) target price on Fresenius SE & Co KGaA (FRA:FRE) in a research report report published on Friday, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock. Several other brokerages also recently weighed in on FRE. Barclays set a €54.00 ($62.79) target price on shares of […]
- 02/24/2020
|
Fresenius SE & Co KGaA (FRA:FRE) Given a €72.10 Price Target at Berenberg Bank
- Fresenius SE & Co KGaA (FRA:FRE) has been given a €72.10 ($83.84) price target by stock analysts at Berenberg Bank in a research report issued on Monday, Borsen Zeitung reports. The firm presently has a “buy” rating on the stock. Berenberg Bank’s price objective would indicate a potential upside of 45.19% from the stock’s current […]
- 02/24/2020
|
Fresenius Medical Care North America Says FDA Has Cleared Novalung For Treatment Of Acute Respiratory Or Cardiopulmonary Failure; Expects Novalung To Be Available Within US Mid-Year 2020
|
UBS Group Analysts Give Fresenius SE & Co KGaA (FRA:FRE) a €47.00 Price Target
- UBS Group set a €47.00 ($54.65) target price on Fresenius SE & Co KGaA (FRA:FRE) in a report issued on Thursday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock. FRE has been the subject of several other reports. Sanford C. Bernstein set a €52.00 ($60.47) target price on Fresenius […]
- 02/23/2020
|
Fresenius SE & Co KGaA (FRA:FRE) Given a €53.00 Price Target by Goldman Sachs Group Analysts
- Fresenius SE & Co KGaA (FRA:FRE) received a €53.00 ($61.63) target price from equities researchers at Goldman Sachs Group in a note issued to investors on Thursday, Borsen Zeitung reports. The firm currently has a “buy” rating on the stock. Goldman Sachs Group’s price objective indicates a potential upside of 6.73% from the stock’s current […]
- 02/22/2020
|
10 Stock Picks With Peter Lynch Qualities
- Peter Lynch, as manager of the Fidelity Magellan Fund (FMAGX) between 1977 and 1990, rode masterful stock picks to outsize gains. FMAGX delivered average annual total returns of more than 29% to fund investors during his 13-year tenure, clobbering the stock market by over 13 percentage points. A $10,000
- 02/21/2020
|
